Breaking

Sunken Bayesian superyacht lifted partially out of water in salvage operation
Britain’s lawmakers vote to allow assisted dying, after fraught national debate
Trump’s Gulf Arab allies race to avoid all-out war in Iran
Israel has threatened to kill Iran’s supreme leader. Here’s what could come next
The US can end Iran conflict with one call, official from Iran’s presidency says
Trump’s two-week delay on Iran strike decision leaves Israel in limbo
Last BTS member Suga discharged from South Korean military service, paving way for reunion
Armed rebels take control of Heineken facilities in DR Congo’s war-hit east

Business
Politics
World
Investing
Search for:

Investing

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

Canadian Investment Regulatory Organization Trade Resumption – CYG

Allied Critical Metals: Advancing Tungsten Projects in Portugal

E-Power Resources Inc. Announces Closing of Oversubscribed Hard Dollar and Flow-through Private Placements

Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

Your name

Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Categories
- Business (56)
- Investing (236)
- Politics (277)
- World (264)

Disclaimer: TimeFinances.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest

Copyright © 2025 TimeFinances.com | All Rights Reserved

Top

Business
Politics
World
Investing

Type above and press Enter to search. Press Esc to cancel.